We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

46 hedge funds and large institutions have $427M invested in Prevail Therapeutics Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

30% more capital invested

Capital invested by funds: $328M → $427M (+$99.5M)

10% more funds holding

Funds holding: 42 → 46 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
15
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.67M
2
BlackRock
BlackRock
New York
+$3.41M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.28M
4
UBS Group
UBS Group
Switzerland
+$979K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$911K

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$3.67M
2
EC
EcoR1 Capital
California
-$1.84M
3
LCM
Laurion Capital Management
New York
-$1.25M
4
SFM
Sphera Funds Management
Israel
-$1.11M
5
Millennium Management
Millennium Management
New York
-$618K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$219M – – –
RCM
2
RA Capital Management
Massachusetts
$53.2M – – –
EC
3
EcoR1 Capital
California
$35.6M -$1.84M -144,250 -6%
Citadel Advisors
4
Citadel Advisors
Florida
$18.5M +$1.28M +100,003 +9%
BC
5
Boxer Capital
California
$17.8M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$13.8M – – –
BlackRock
7
BlackRock
New York
$11.3M +$3.41M +267,040 +60%
OFM
8
Omega Fund Management
Massachusetts
$10.6M -$13 -1 -0%
BI
9
BVF Inc
California
$10.4M – – –
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$7.85M -$204K -16,000 -3%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$5.8M +$4.67M +366,324 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$4.84M +$911K +71,431 +30%
Bank of America
13
Bank of America
North Carolina
$4.39M +$470K +36,821 +15%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$3.38M +$43.6K +3,419 +2%
State Street
15
State Street
Massachusetts
$1.66M +$546K +42,767 +69%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.56M +$218K +17,099 +21%
Northern Trust
17
Northern Trust
Illinois
$1.29M -$28.9K -2,269 -3%
UBS Group
18
UBS Group
Switzerland
$1.22M +$979K +76,764 New
DCM
19
DAFNA Capital Management
California
$1.19M – – –
AS
20
Altshuler Shaham
Israel
$799K – – –
Squarepoint
21
Squarepoint
New York
$319K +$257K +20,154 New
CI
22
Clal Insurance
Israel
$292K -$3.67M -287,378 -98%
N
23
Nuveen
North Carolina
$282K -$83.9K -6,576 -27%
Charles Schwab
24
Charles Schwab
California
$248K – – –
Goldman Sachs
25
Goldman Sachs
New York
$247K +$199K +15,579 New
1
2 3

PRVL Hedge Fund Activity: Q4 2019 in Review

46 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2019, worth a combined $427M — up 30% from $328M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new PRVL positions and 6 closed out — a net gain of 4 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.67M. The largest seller was Clal Insurance, cutting an estimated $3.67M.

  • 46 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2019, up from 42 in Q3 2019.
  • Funds reported $427M of Prevail Therapeutics Inc. Common Stock stock for Q4 2019, up 30% quarter-over-quarter.
  • 10 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2019 and 6 closed out, a net change of +4 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2019 was Point72 Asset Management, an estimated $4.67M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2019 was Clal Insurance, an estimated $3.67M sold.

Based on aggregated 13F filings for Q4 2019.